Navigation Links
EAU Technologies Receives Patent for Empowered Water(TM)
Date:1/22/2009

Solution for mold remediation provides environmentally friendly alternative to currently used chemicals.

ATLANTA, Jan. 22 /PRNewswire-FirstCall/ -- EAU Technologies, Inc. ("EAU" or "Company") (OTC Bulletin Board: EAUI), a leading provider of electrolyzed oxidative water, announced today its receipt of Patent #US7,445,800 B2, from the United States Patent Office, to use Empowered Water(TM) Primacide A and C for mold remediation.

Empowered Water(TM) Primacide A and Primacide C are produced by EAU's state-of-the-science generators using a unique combination of cell technology, salt and electricity to alter the molecular structure of water to create a non-toxic, oxidized antimicrobial solution. Empowered Water(TM) Primacide solutions are disinfecting fluids that kill a variety of pathogens including bacteria, viruses, molds and spores, within seconds of contact.

EAU conducted successful protocol studies for the use of Empowered Water(TM) in mold remediation with an industry-leading research firm. Results demonstrated dramatic reductions of mold counts on contaminated surfaces without the use of toxic chemicals.

"In entering any new channel, we first must conduct extensive research to prove the application. Following that, we protect it as best as we can while we develop a realistic business model and find an industry partner to assist with rolling out the technology," said Wade Bradley, CEO of EAU Technologies, Inc. "Mold remediation proved very effective early on. As mold is a major cause of asthma and respiratory problems, especially in children, we are confident that the use of our non-toxic solutions will contribute to a shift in how the industry approaches remediation in this area."

Bradley added that EAU is actively involved in commercializing industrial applications for Clean-in-Place (CIP), Poultry Processing and in Dairy applications.

About EAU:

EAU Technologies, Inc. (EAU) is a supplier of Electrolyzed Water Technology (EW Technology marketed as Empowered Water(TM)) and other complementary technologies with applications in diverse industries. EAU's water-based and non-toxic solutions (at application concentration, the solutions are non-toxic to humans and live animals) may replace many of the traditional methods now used to clean, disinfect and nourish in large industries such as agriculture and food processing. EAU has solutions for existing bacteria, virus and mold proliferation threats. EAU continues to add innovative and efficacious products that offer a systemic approach to pathogen elimination in food processing plants and related industries, thereby producing safer foods while protecting the environment through "Green Technology." EAU has developed patent pending systems that are being used on dairies to process drinking water for dairy herds. Studies and trials are showing promising results at improving animal digestion which shows signs of improved animal health and production. EAU uses terms like "green", "natural", "non-toxic" and "organic" based on our NAMSA studies that show no toxicity or cytotoxicity at levels as high as 70 ppm of HOCl. EAU uses only water, food grade electrolytes and electricity to create all of its solutions. The active ingredients in the solutions EAU creates through electrolysis are GRAS (generally regarded as safe) approved. Please visit our website and sign up to be emailed our press releases and public announcements. www.eau-x.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may include without limitation, our expectations about the growth and the potential for the company, and Mr. Bradley's abilities to lead the company in that growth. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk associated with successfully developing our business in evolving markets, our need for additional capital, our continuing operating losses, the ability of our management to conduct distribution activities and sell products, possible failure to successfully develop new products, vulnerability to competitors due to lack of patents on our products, and other risk factors listed in our annual report on Form 10-KSB for the year ended December 31, 2007 and our other SEC reports. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.


'/>"/>
SOURCE EAU Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
2. BASF and Monsanto Formalize Agreement to Develop Dicamba-Based Formulation Technologies
3. Neurobiological Technologies Announces Suspension of Viprinex Development
4. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
5. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
6. Volcano Announces Closing of Axsun Technologies Acquisition
7. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
8. ISTO Technologies to Present at OneMedPlace Emerging Company Finance Conference
9. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
10. BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative
11. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  Driven by consumers, preference towards ... the fastest growing categories, finds the recently published ... Personal Care: Multi-regional Market Analysis and Opportunities ... firm Kline. "Biotechnology actives are derived ... more effective for skin and hair care applications," ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
(Date:2/23/2017)... LONDON and NEW YORK ... at HIMSS, Lumeon , a leading digital ... (DN Telehealth), a provider of telemedicine and remote ... care pathways for telemedicine reimbursements.  ... and their patients, in real-time, extending consultations beyond ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):